• The New Money
  • Posts
  • Tokenized Stocks On Solana, Spodumene Supply For Batteries, And A New Zcash ETF

Tokenized Stocks On Solana, Spodumene Supply For Batteries, And A New Zcash ETF

The markets and trends that matter, made simple. Discover what’s next.

October 10, 2026

Securitize Launches 12 New Tokenized Stocks On Solana

Securitize (NYSE: SECZ) launched 1:1 backed tokenized shares of 12 stocks on Solana, including Tesla (NASDAQ: TSLA), Meta Platforms (NASDAQ: META), Circle Internet Group (NYSE: CRCL) and Palantir (NASDAQ: PLTR). Securitize publicly stated that they are aiming to bring these 12 new tokenized stocks to the New York Stock Exchange’s digital asset trading platform upon regulatory approval.

Elevra Lithium Secures Spodumene Supply Deal With LG Energy Solution

Elevra Lithium (NASDAQ: ELVR) signed a binding deal to supply LG Energy Solution with 240,000 dry metric tonnes of spodumene concentrate. marking the single largest supply deal that Elevra has ever entered with a battery maker.

Cameron and Tyler Winklevoss Want To Launch A Zcash ETF

Cameron and Tyler Winklevoss have filed a Form S-1 with the United States Securities and Exchange Commission to list The Winklevoss Zcash ETF on the Nasdaq. This is the first time ever that Cameron and Tyler Winklevoss have launched an ETF application for a digital asset outside of Bitcoin.

GLP-1 Weight Loss Drugs Are Creating A New Multi-Billion Dollar Market For Medical Aesthetics

GLP-1 weight loss can strip fat faster than skin can adapt, leaving loose skin, hollowed cheeks and a loss of fullness across the face and body. Conexeu Sciences (NASDAQ: CNXU) is targeting that growing aesthetic need with CXU™, an injectable platform in preclinical development designed to support tissue regeneration and restore lost volume.

The Sprint

The Markets This Week

+31.1% | Cango Inc.

+19.8% | Sezzle

+18.4% | Moderna

+18.0% | Talon Energy

+15.4% | Vistra

Top Trends This Week

Looking to connect? Reach out and get in touch.

New here? Join our community of 100,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.